TMCnet News
Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement
IRVINE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Biomerica Inc. (Nasdaq: BMRA), is proud to announce a multi-year exclusive distribution agreement with one of the UAE's most substantial healthcare conglomerates. This strategic alliance is set to revolutionize the accessibility and efficiency of colorectal cancer screening and breast examination technologies in the region. Strategic Partnership Highlights The collaboration between Biomerica and its UAE partner reflects a shared vision of reducing the burden of cancer through early detection and innovative healthcare solutions. The companies are also exploring opportunities to introduce additional Biomerica products to the UAE, expanding their impact on healthcare improvement. EZ Detect™: Colorectal Screening Made Easy Aware®: Pioneering Breast Health Self-Exams Broader Health Impacts and Company’s Commitment Colorectal Cancer In a study performed by Johns Hopkins University, EZ Detect™ was preferred 10 to 1 by patients over another fecal occult blood test. Published studies have also indicated that the best colorectal screening test is “the one that gets it done” [2]. Other colorectal screening tests require handling of the stool and sending the stool sample to a lab for processing, which can prove cumbersome. Because of the unpleasant difficulties of handling and mailing stool samples, a high percentage of these competing tests are never completed by patients [3]. This potentially increases the risk for delayed detection of colorectal cancer. Breast Cancer For further information about the EZ Detect Product, please visit www.ezdetect.com For further information about the Aware Product, please visit www.awarebse.com About Biomerica (NASDAQ: BMRA) Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica’s primary focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
Safe Harbor Statement The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the efficacy of the Company’s EZ Detect and other tests, FDA clearance of the Company’s products, integrating into national health protocols, the number of stores where the EZ Detect and other products are or will be sold or available, the rapidity of testing results, negotiations with existing and new domestic and international distribution partners, uniqueness of the Company’s products, test result accuracy of products, potential for the products to detect signs of cancer and other diseases, pricing of the Company’s test kits, demand for domestic or international orders, potential revenues from the sale of the EZ Detect test And Aware in the UAE or through other distribution channels, or from the sales of other products, availability of the Company’s test kits, and patent protection on any of the Company’s products or technologies. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: results of studies testing the efficacy of the Company’s EZ Detect test, Aware product, InFoods tests and other products; regulatory approvals necessary prior to commercialization of the Company’s products; availability of the Company’s test kits and other products; capacity, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; the Company’s ability to comply with current and future regulations in the countries where our products are made and sold and the Company’s ability to obtain patent protection on any aspects of its rapid test technologies. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release. Corporate Contact: Zack Irani Source: Biomerica, Inc. |